Drug Trial Radar · NCT04358770
Bio-equivalence Vasoconstriction Activity Study for Topically Applied Clocortolone Pivalate 0.1% Cream
Last checked: Nov 20, 2026Latest source record: Apr 24, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
124
Actual
Start
Mar 2, 2018
Primary completion
Apr 27, 2018
Study completion May 11, 2018
Sponsor
- Lead sponsor
- Sun Pharmaceutical Industries, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- WAYCro
- First posted
- Apr 24, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Health services research
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 35 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To compare pharmacodynamic vasoconstriction response profile of Clocortolone Pivalate 0.1% Cream and Cloderm® (Clocortolone Pivalate) 0.1% Cream in normal skin of healthy male and female adults
Conditions
- Bioequivalence Study
Interventions
Clocortolone PivalateDrug
Cream, 0.1%
Primary outcomes
What the sponsor says the trial is designed to measure.
- AUEC0-24 (area under the effect curve)Time frame: 24 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
WayCro
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.